Anixa Biosciences, Inc.
ANIX
$3.38
-$0.17-4.79%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.34% | 8.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.31% | 7.05% | |||
| Operating Income | 11.31% | -7.05% | |||
| Income Before Tax | 12.45% | -10.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.45% | -10.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -20.69% | -3.33% | |||
| Net Income | 12.37% | -10.44% | |||
| EBIT | 11.31% | -7.05% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 12.44% | -10.38% | |||
| Normalized Basic EPS | 12.36% | -10.61% | |||
| EPS Diluted | 12.44% | -10.38% | |||
| Normalized Diluted EPS | 12.36% | -10.61% | |||
| Average Basic Shares Outstanding | 0.02% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||